S100A5 Attenuates Efficiency of Anti‐PD‐L1/PD‐1 Immunotherapy by Inhibiting CD8(+) T Cell‐Mediated Anti‐Cancer Immunity in Bladder Carcinoma

Although immune checkpoint blockade (ICB) therapies have been approved for bladder cancer (BLCA), only a minority of patients respond to these therapies, and there is an urgent need to explore combined therapies. Systematic multi‐omics analysis identified S100A5 as a novel immunosuppressive target f...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Huihuang, Chen, Jinbo, Li, Zhenghao, Chen, Minfeng, Ou, Zhenyu, Mo, Miao, Wang, Ruizhe, Tong, Shiyu, Liu, Peihua, Cai, Zhiyong, Zhang, Chunyu, Liu, Zhi, Deng, Dingshan, Liu, Jinhui, Cheng, Chunliang, Hu, Jiao, Zu, Xiongbing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477882/
https://www.ncbi.nlm.nih.gov/pubmed/37414584
http://dx.doi.org/10.1002/advs.202300110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477882/
https://www.ncbi.nlm.nih.gov/pubmed/37414584
http://dx.doi.org/10.1002/advs.202300110

Ejemplares similares